Lv41
690 积分 2023-07-19 加入
MYC rearrangement and MYC/BCL2 double expression but not cell‐of‐origin predict prognosis in R‐CHOP treated diffuse large B‐cell lymphoma
1小时前
待确认
Challenges facing CAR T-cell immunotherapy in multiple myeloma
3天前
已完结
CAR T-cell therapy for multiple myeloma: state of the art and prospects
3天前
已完结
CAR-T for multiple myeloma: practice pearls
3天前
已完结
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
3天前
已完结
CAR T-cell therapy to treat multiple myeloma: current state and future directions
3天前
已完结
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
24天前
已完结
European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma
24天前
已完结
Long-term therapy outcomes of CD19/22 CAR T-cell alone or with autologous stem cell transplantation for relapsed/refractory DLBCL
1个月前
已完结
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
2个月前
已完结
皖公网安备34019202002308
